Spero Therapeutics Current Ratio 2016-2021 | SPRO

Spero Therapeutics current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Spero Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.11B $0.01B 8.29
2021-03-31 $0.13B $0.02B 7.29
2020-12-31 $0.14B $0.01B 9.70
2020-09-30 $0.14B $0.02B 8.12
2020-06-30 $0.09B $0.02B 4.49
2020-03-31 $0.10B $0.02B 4.31
2019-12-31 $0.10B $0.03B 3.58
2019-09-30 $0.10B $0.02B 6.91
2019-06-30 $0.11B $0.01B 13.66
2019-03-31 $0.12B $0.01B 17.48
2018-12-31 $0.12B $0.01B 10.08
2018-09-30 $0.13B $0.01B 13.01
2018-06-30 $0.07B $0.01B 10.68
2018-03-31 $0.08B $0.01B 13.67
2017-12-31 $0.09B $0.01B 11.29
2017-09-30 $0.03B $0.01B 3.92
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
2016-09-30 $0.00B 0.00
2015-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.620B $0.009B
Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71